Fontanet Bijou

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 305 citations · Full text

Neuro-oncology, Primary Vitreoretinal Lymphoma, Lymphoid Neoplasia +6

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

Emmanuelle Tchernonog, P. Faurie, Paul Coppo et al. · Annals of Oncology · 2016 · 124 citations

Hematological Malignancy, Lymphoid Neoplasia, Health Sciences +11

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet et al. · American Journal of Hematology · 2018 · 116 citations · Full text

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

Anna L. Godfrey, Edwin Chen, Francesca Pagano et al. · Blood · 2012 · 102 citations · Full text

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Franck Morschhauser, Steven Le Gouill, Pierre Feugier et al. · The Lancet Haematology · 2019 · 91 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +4